GLP-1 & Metabolic Peptides
Exenatide
Commonly used for
DiabetesAppetite ControlMetabolic Health
What is it?
Exenatide was the first GLP-1 receptor agonist. It is a synthetic version of exendin-4, a peptide originally isolated from the saliva of the Gila monster (Heloderma suspectum). It improves glycemic control by enhancing glucose-dependent insulin secretion, reducing glucagon release, slowing gastric emptying, and promoting satiety.
Brand names: Byetta® (twice daily), Bydureon BCise® (once weekly)
Mechanism of action: GLP-1 receptor agonist; Enhances glucose-dependent insulin secretion; Suppresses glucagon secretion; Slows gastric emptying; Reduces appetite and food intake; Promotes modest weight loss
What do people use it for?
Approved indications: Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
Proposed indications: Obesity; Prediabetes; Metabolic syndrome; NAFLD/MASH; Cardiovascular risk reduction
How is it used? / Dosing
Administration: Subcutaneous injection — Twice daily (Byetta) or once weekly (Bydureon BCise)
How does it compare?
Compare with:
How well does it work? / Evidence
✓ Well-established
Evidence rating: Grade A — Supported by multiple randomized controlled trials and over 15 years of clinical use.
Landmark trials: AMIGO clinical trial program — Established efficacy in type 2 diabetes.; EXSCEL Trial — Evaluated cardiovascular outcomes and demonstrated cardiovascular safety without superiority for major adverse cardiovascular events.
Safety & side effects
Common side effects: Nausea, Vomiting, Diarrhea, Constipation, Injection-site reactions (weekly formulation), Decreased appetite
Serious risks: Acute pancreatitis; Acute kidney injury (often related to dehydration); Severe gastrointestinal adverse effects; Hypoglycemia when combined with insulin secretagogues
Drug interactions: Delayed gastric emptying may affect absorption of oral medications; Increased hypoglycemia risk with sulfonylureas or insulin
Monitoring: HbA1c, Fasting glucose, Renal function, Weight, Gastrointestinal tolerance
Legal & regulatory status
Legal status: Prescription required. This is an FDA-approved medication available only through a licensed prescriber — dosing is determined by your prescriber based on your medical history and is not provided here.
Regulatory status: FDA Approved • EMA Approved
Who should avoid it?
Contraindications: Serious hypersensitivity to exenatide; History of severe gastrointestinal disease (use caution); Not recommended in patients with severe renal impairment or end-stage renal disease
Pregnancy & breastfeeding: Not recommended during pregnancy. Limited human data are available. Safety during breastfeeding has not been established.
Research & references
Holman RR, et al. (2017). Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes (EXSCEL). New England Journal of Medicine, 377(13), 1228–1239. https://doi.org/10.1056/NEJMoa1612917 Drucker DJ, et al. (2008). Exenatide once weekly versus twice daily for the treatment of type 2 diabetes. The Lancet, 372(9645), 1240–1250. https://doi.org/10.1016/S0140-6736(08)61206-4